tiprankstipranks
Zealand Pharma’s (NASDAQ:ZEAL) Phase 3 SBS Trial Sees Positive Results
Market News

Zealand Pharma’s (NASDAQ:ZEAL) Phase 3 SBS Trial Sees Positive Results

Biotechnology company Zealand Pharma (NASDAQ:ZEAL) has delivered positive topline results from the Phase 3 trial of glepaglutide for the treatment of short bowel syndrome (SBS).

The trial met its primary endpoint and the twice-weekly dosing regimen showed a statistically significant decrease in weekly parental support at 24 weeks.

The treatment was deemed safe and was well tolerated.

Is Zealand Pharma Stock Good?

The Street currently has a Moderate Buy consensus rating on Zealand stock alongside an average price target of $32 which indicates an 81.92% potential upside for ZEAL stock.

Read full Disclosure

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles